

Dresden/King's college Transcampus professorship for hematology/oncology

Research topic(s):

Allogeneic stem cell transplantation, Cellular therapy, Adoptive immunotherapy, Cell biology of mesenchymal and hematopoietic stem cells, Targeted therapy, Adoptive transfer of t-cells.



Prof. Dr. med. Martin Bornhäuser
Department of Internal Medicine I
University Hospital Carl Gustav Carus
Fetscherstraße 74
01307 Dresden
Ph.: +49-351-458 4704
Fax: +49-351-458 5362

E-mail: Martin.Bornhaeuser@uniklinikum-dresden.de

<https://www.uniklinikum-dresden.de/das-klinikum/kliniken-polikliniken-institute/mk1>

Education:

1986-1993 Study of medicine, Kiel, Germany
1989-1991 Doctoral thesis
2001 Habilitation for Internal Medicine, Dresden, Germany

Training:

1993-1994 Fellowship, Hematology/Oncology, University Hospital, Tübingen, Germany
1994 Stem Cell Laboratory, Department for Pediatrics, Tübingen, Germany
1995-1998 Internship, University Hospital, Dresden, Germany
1999 Board Certification for Internal Medicine
2000 Board Certification for Hematology/Oncology
2002 Certified Member of the European Society for Medical Oncology

Clinical Experience:

Hematology/Oncology, Autologous and allogeneic stem cell transplantation, High-dose chemotherapy, Acute leukemias.

Professional Appointments:

1998-2003 Senior physician
2004 Head of Stem Cell Transplant Program, University Hospital, Dresden, Germany
2004 Endowed C3-Professorship Stem Cell Transplantation, Dresden, Germany
2009 W3 Professorship for Translational Biomedical Research
2011 W3 Professorship Hematology/Oncology

Publications: 340 publications in scientific journals and books, of these 320 peer-reviewed (aus CV DKTK)

Funding: Extrabudgetary funding by Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe, BMBF, SMWK, Jose Carreras foundation, German Bone Marrow donor registry (DKMS), Roland-Pfleger Stiftung.

Awards: Otto-Rostoski Award of the Dresden Cancer Center
van Bekkum Award (EBMT)

Group members:

Senior physicians Prof. Dr. U. Platzbecker, Prof. Dr. J. Schetelig, Prof. Dr. R. Ordemann, PD Dr. C. Röllig

Scientists Dr. Manja Wobus

PhD students: Abishek Dhawan, Martin Kräter,

Dresden Internal collaborators:

Marc Schmitz, A. Roers, Michael Bachmann, Institute of Immunology

Meinolf Suttorp, Sebastian Brenner, Department of Pediatrics

Michael Baumann, Department of Radiation Oncology.

Jörg Kotzerke, Department of Nuclear Medicine

External collaborators:

Carsten Werner - Leibniz Institute of Polymere Research/Max Bergmann Center of Biomaterials Dresden, National Cancer Institute, Bethesda, USA, Fred Hutchinson Cancer Research Center, Seattle, USA

Participation in collaborative research projects (local, national, international):

Local: SFB 655 (www.sfb655.de), Cells into tissues; DFG-Forschungszentrum and Excellence Cluster: Centre for Regenerative Therapies, Dresden (www.crt-dresden.de)

National: Coordinator of the Cooperative German Transplant Study group

International: Fred Hutchinson Cancer Research Centre, Seattle, USA (Trial on minimal conditioning vs. standard therapy in AML/MDS)

List of 10 most important publications 2005–2015:

1. Theil A, Tuve S, Oelschlagel U, Maiwald A, Dohler D, Ossmann D, Zenkel A, Wilhelm C, Middeke JM, Shayegi N, Trautmann-Grill K, von BM, Platzbecker U, Ehninger G, Bonifacio E, **Bornhäuser M** (2015): Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. *Cytotherapy*. 17, 473-486.
2. Röllig C, Knop S, **Bornhäuser M**. Multiple Myeloma. *Lancet*. 2015 doi: 10.1016/S0140-6736(14)60493 -1
3. Prewitz MC, Seib FP, von BM, Friedrichs J, Stissel A, Niehage C, Muller K, Anastassiadis K, Waskow C, Hoflack B, **Bornhäuser M**, Werner C. Tightly anchored tissue-mimetic matrices as instructive stem cell microenvironments. *Nat Methods*. 2013;10:788-94.
4. Duryagina R, Thieme S, Anastassiadis K, Werner C, Schneider S, Wobus M, Brenner S, **Bornhäuser M**. Overexpression of Jagged-1 and its intracellular domain in human mesenchymal stromal cells differentially affect the interaction with hematopoietic stem and progenitor cells. *Stem Cells Dev*. 2013;22:2736-50.
5. **Bornhäuser M**, Kienast J, Trenscher R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. *Lancet Oncol*. 2012;13:1035-44.

6. **Bornhäuser M**, Thiede C, Platzbecker U, Kiani A, Oelschlaegel U, Babatz J, Lehmann D, Holig K, Radke J, Tuve S, Wermke M, Wehner R, Jahnisch H, Bachmann MP, Rieber EP, Schetelig J, Ehninger G, Schmitz M. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. *Blood*. 2011;117:7174-84.
7. **Bornhäuser M**, Aringer M, Thiede C. Mixed lymphohematopoietic chimerism and response in Wegener's granulomatosis. *N Engl J Med*. 2010;362:2431-2.
8. von Bonin M, Stolzel F, Goedecke A, Richter K, Wuschek N, Holig K, Platzbecker U, Illmer T, Schaich M, Schetelig J, Kiani A, Ordemann R, Ehninger G, Schmitz M, **Bornhäuser M**. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. *Bone Marrow Transplant*. 2009;43:245-51.
9. **Bornhäuser M**, Illmer T, Oelschlaegel U, Schetelig J, Ordemann R, Schaich M, Hanel M, Schuler U, Thiede C, Kiani A, Platzbecker U, Ehninger G. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia. *Clin Cancer Res*. 2008;14:5585-93.
10. Stelljes M, **Bornhäuser M***, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J. Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. *Blood*. 2005;106:3314-21. *shared first authorship

Projects together with PI's from King's:

- Clinical trials in allogeneic transplantation (Prof. G. Mufti, Prof. V. Potter, Prof. F. Farzaneh)
- Role of mesenchymal stromal cells for immunodulation (Prof. F. Dazzi)
- Cellular immunotherapy (Prof. Farzaneh, Prof. Mufti)
- Myelodysplastic syndromes (MDS) and preleukemia (Prof. G. Mufti)
- Targeted therapy in Acute myeloid leukemia (AML) (Prof. G. Mufti)